SCHEMBL259199

SCHEMBL259199

COc1ccc(C(=O)Nc2c(C(N)=O)[nH]c3ncccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.51
RAB9A P51151 9/20 0.50
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 7/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 2/20 0.47
ADORA3 P0DMS8 1/20 0.46
PPARG P37231 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
F10 P00742 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.44
CDK5 Q00535 1/20 0.44
PAX8 Q06710 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259196 0.86 ALDH1A1 (0.47) F2RAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL13298528 0.76 MAPT (0.56) F2RAB9AKMT2ALMNANPC1
SCHEMBL259336 0.75 MAPT (0.49) F2RAB9AKMT2ANPC1MAPT
SCHEMBL259347 0.74 RAB9A (0.53) RAB9AKMT2ALMNAPOLBNPC1
SCHEMBL259189 0.74 MAPT (0.71) KMT2ALMNASMN1; SMN2MAPTADORA3
SCHEMBL259185 0.73 MAPT (0.60) KMT2ASMN1; SMN2MAPTALDH1A1GAA
SCHEMBL6257175 0.71 KMT2A (0.69) RAB9AKMT2ALMNANPC1SMN1; SMN2
SCHEMBL259192 0.70 MAPT (0.56) F2RAB9AKMT2ALMNAPOLB
SCHEMBL27520433 0.70 HDAC1 (0.62) F2RAB9AKMT2ALMNAPOLB
SCHEMBL6259345 0.70 KDR (0.61) RAB9AKMT2ALMNANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A F2 4693/4885RAB9A 613/4885KMT2A 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.